Vazkepa From Amarin Gets Recommended By NICE In The U.K
Amarin has earned a much-needed triumph internationally after faltering in the crucial US market. Vazkepa has been approved by the National Institute for Health...
After Lupin Deal Teva Holds Another Austedo Rival To 2033
Teva can rest easy knowing that it does have a long runway free of generics—at least from two major challengers—as it focuses on the...
Rejected By The FDA, NICE Endorses The Anaemia Drug Evrenzo
Despite a high-profile FDA denial, FibroGen and its collaborators have been able to expand into new markets outside of the United States with Evrenzo,...
Time Congress Acts As Drug Launch Prices Go Up 20% Annually
As many Americans face difficult financial decisions thanks to inflation, a new study verifies what many have feared for years: drug prices are significantly...
Bluebird Gene Therapy Given FDA Nod Despite Safety Issues
Bluebird bio has persuaded an expert committee that the benefits of its gene therapy possibility, eli-cel, exceed the risks, at least in certain patients,...
Alnylam Gives Findings of siRNA Delivery Outside of Liver
Alnylam has outlined their strategy for delivering siRNA to the central nervous system and other organs outside of the liver. The RNA specialist detailed...
Merck Sees 80 Plus Cancer Patents By 2028 Led By Keytruda
Merck & Co. was not at all a prominent oncology player before the advent of Keytruda. The New Jersey drugmaker wants to consolidate its supremacy...
Subscribe Our Newsletter
White Papers
The Future of Digital Health
The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....
Five Best Practices to Deliver Exceptional Multichannel Experiences
A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...
The Impact and Use of Social Media in Pharmacovigilance
Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...